| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,392 |
6,236 |
$633K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,012 |
2,009 |
$287K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,716 |
1,684 |
$126K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,218 |
1,217 |
$114K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,724 |
1,693 |
$87K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
514 |
511 |
$44K |
| 87428 |
|
1,432 |
1,419 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
475 |
472 |
$21K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
538 |
536 |
$18K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
770 |
766 |
$11K |
| 87430 |
|
639 |
630 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
316 |
316 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
150 |
148 |
$8K |
| 99051 |
|
1,141 |
1,135 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
20 |
19 |
$802.80 |
| 87400 |
|
25 |
25 |
$314.25 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
17 |
15 |
$263.15 |